An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

NCT ID: NCT01026376

Last Updated: 2013-04-18

Basic Information

• Recruitment Status: NO_LONGER_AVAILABLE
• Study Classification: EXPANDED_ACCESS
• Study Start Date: 2008-06-30
• Study Completion Date: 2011-11-30

Brief Summary

The purpose of this study is to provide Decitabine to patients with Myelodysplastic syndrome (MDS) of all FAB (French-American-British) subtypes and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups, including both previously treated and untreated patients.

Detailed Description

Myelodysplastic Syndromes (MDS), which includes a diverse group of bone marrow disorders that result in ineffective production of blood cells, frequently occurs in elderly patients. Historically, the available treatments for MDS have been symptomatic and supportive, and have not been shown to be effective in producing sustained improvement in hematopoiesis (production of all types of blood cells ) or in delaying leukemic evolution (leukemia is a serious disease in which too many white blood cells are produced, causing weakness and sometimes death). This project is an open-label (all people involved know the identity of the intervention), multicenter, international single arm, Phase 3b study to provide expanded access to Decitabine for patients with myelodysplastic syndromes (MDS). The purpose of this study is to provide Decitabine to patients with Myelodysplastic syndrome (MDS) according some medical classifications: FAB (French-American-British) subtypes and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups, including previously treated and untreated for MDS. The secondary objectives are to evaluate the safety and tolerability of Decitabine, as well as the overall response rate according to the International Working Group (IWG) 2000 and IWG 2006 response criteria, hematologic improvement, cytogenetic response rates (evaluation based on genetic), time to acute myeloid leukemia progression or death (evaluate the length of time that passes prior to onset of leukemia progression and/or death), blood product transfusion requirements per patient (with corresponding dates to collect the number of transfusion independent days), days in the hospital (including reason for hospitalization and the ward within the hospital where the hospitalizations occur) and, optionally, quality of life assessment (EORTC QLQ C-30). 3-day cycle: Decitabine will be administered as a 15mg/m2 administered by continuous infusion over 3 hours repeated every 8 hours for 3 days. 5-day cycle: Another optional schedule could be adopted (at discretion of investigators), Decitabine at a dose of 20mg/m² administered intravenously over 1 hour, once daily for 5 consecutive days, of a 4-week cycle. Treatment may be continued as long as the patient continues to benefit.

Conditions

Myelodysplastic Syndromes

Interventions

decitabine

Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days

Intervention Type: DRUG

decitabine

Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Must have a diagnosis of MDS (de novo / primary or secondary) of all FAB subtypes and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups
• Has an Eastern Oncology Cooperative Group (ECOG) performance status of 0-2
• Adequate hepatic and renal function as measured by the following pre-treatment laboratory criteria within 21 days of starting treatment with Decitabine (laboratory measure of liver function no more than 2.5 times the upper limit of normal, laboratory measure of total bilirubin and serum creatinine no more than 1.5 times the upper limit of normal)
• Female patients must be postmenopausal, or surgically sterile, or abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study
• Have a negative serum or urine pregnancy test at screening
• Male subjects should be advised not father a child while on or within 2 months of completion of Decitabine therapy

Exclusion Criteria

• Have a diagnosis of AML (>20% bone marrow blasts) or other progressive malignant disease
• has previously been treated with Azacitidine or Decitabine
• Have uncontrolled heart disease or uncontrolled congestive heart failure
• Have uncontrolled restrictive or obstructive pulmonary disease
• Have active viral or bacterial infection
• Have known positive serology for HIV
• Have a mental illness or any other condition that could prevent full cooperation with the treatment and monitoring requirements of the study
• Have known hypersensitivity to any of the excipients of decitabine
• Are pregnant or breast-feeding

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Korea, Ltd., Korea

INDUSTRY

Sponsor Role: collaborator

Janssen-Cilag Farmaceutica Ltda.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen-Cilag Farmaceutica Ltda. Clinical Trial

Role: STUDY_DIRECTOR

Janssen-Cilag Farmaceutica Ltda.

Locations

Belo Horizonte, , Brazil

Botucatu, , Brazil

Brasília, , Brazil

Campinas, , Brazil

Fortaleza, , Brazil

Pinheiros, , Brazil

Rio de Janeiro, , Brazil

São Paulo, , Brazil

São Paulol, , Brazil

Hong Kong, , Hong Kong

Bangkok, , Thailand

Countries

Brazil; Hong Kong; Thailand

Other Identifiers

DACOGENMYE3001

Identifier Type: OTHER

Identifier Source: secondary_id

CR015037

Identifier Type: -

Identifier Source: org_study_id